Fluorocarbon MRI Reagents for Inflammatory Cell Labeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for accurately delivering biological materials to injured internal organs, such as those affected by myocardial infarction, face challenges due to the lack of precise targeting and effective imaging techniques for inflammation, leading to inefficiencies in treating conditions like MI and other inflammatory responses.
Innovation Solution
The use of fluorine-19 (19F) magnetic resonance imaging (MRI) fluorocarbon imaging reagents to label inflammatory cells, allowing for precise detection and boundary identification between healthy and affected tissue, enabling targeted delivery of medicaments through image-guided treatment methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used to detect inflammatory cells, then the imaging process is simple and widely available, but the precision and specificity of inflammation detection is insufficient
Solution Approach 1:
The patent introduces fluorocarbon imaging reagents as an intermediary substance that specifically binds to inflammatory cells. These reagents contain fluorine-19 nuclei that can be detected by MRI, serving as a mediator between the inflammatory cells (target) and the MRI scanner (detection device). This allows conventional MRI equipment to detect inflammatory cells with high precision without requiring complex new imaging hardware.
Solution Approach 2:
The patent changes the detection parameter from detecting endogenous tissue signals to detecting exogenous fluorine-19 signals introduced via imaging reagents. By administering fluorocarbon compounds that accumulate in inflammatory cells, the method transforms the detection target from natural tissue properties to introduced fluorine-containing molecules, enabling specific inflammation visualization with standard MRI equipment.
2Manufacturing precision
If biological materials are administered without precise targeting, then the treatment process is simple and quick, but the delivery accuracy to injured tissue is insufficient
Solution Approach 1:
The patent performs preliminary imaging to identify the precise location and boundaries of injured tissue before administering the medicament. The fluorocarbon imaging reagents are administered first to label inflammatory cells, then 19F MRI is performed to map the affected areas. This preliminary localization enables subsequent precise targeting of biologics to the exact injury site, improving delivery accuracy while maintaining operational simplicity through a sequential two-step process.
3Reliability
If early intervention after MI is performed to minimize scar burden, then the therapeutic effect is maximized, but the timing window requires rapid and accurate diagnosis
Solution Approach 1:
The patent replaces conventional anatomical imaging methods with molecular-specific imaging using fluorine-19 MRI. Instead of relying on structural changes that appear later in the disease process, the method detects inflammatory cells at the molecular level through fluorocarbon reagent binding. This substitution enables earlier and more reliable diagnosis of acute MI inflammation, providing the rapid and accurate diagnosis needed for timely intervention within the critical therapeutic window.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate and timely delivery of medicaments to areas of inflammation, potentially reducing scarring and enhancing tissue renewal in conditions like MI, while also being applicable to other inflammatory responses in various internal organs.
Implementation Method 1
administering a fluorine-19 (19F) magnetic resonance imaging (MRI) fluorocarbon imaging reagent to said subject to label inflammatory cells, performing 19F MRI of the subject to detect labeled inflammatory cells
Data Source
AI summary
The disclosure provides, in part, fluorocarbon imaging reagents and methods for image-guided treatment and/or diagnosis of a subject with a condition associated with an inflammatory response in an internal organ. The disclosure additionally provides methods for image-guided treatment of myocardial infarction (MI) in a subject.